Only 15000 applicants so 'rare' side effects is still a valid argument if it indeed saved lives. 70+ was the at-risk group though, and I'll bet a huge % of these poor people are under 70. More of this to come, you can be certain of that. Great play by big pharma to safeguard sales into the future. Bravo.